Indication

For the treatment of 5q spinal muscular atrophy (SMA) in patients two months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 copies.

Medicine details

Medicine name:
risdiplam (Everysdi)
SMC ID:
SMC2401
Pharmaceutical company
Roche
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Publication due date:
07 February 2022
SMC meeting date:
11 January 2022
Patient group submission deadline:
04 October 2021